Lantus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

A Study of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
Conditions:   Type 2 Diabetes;   Type 2 Diabetes Treated With Insulin Interventions:   Drug: LY3209590;   Drug: Insulin Lispro (U100);   Drug: Insulin Glargine (U100) Sponsor:   Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 18, 2022 Category: Research Source Type: clinical trials